Home

WESEEYOUâ„¢

Intercept’s commitment to research is a commitment to you

The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.

LEARN ABOUT PBC AND NASH >

News

Monday, January 12, 2015
Intercept Provides 2014 Year-End Update and Planned 2015 Milestones

See the press release >